Learn about teprotumumab for moderate to severe thyroid eye disease, its benefits, risks, as well as evolving treatment ...

Last year, the U.S. FDA approved Tepezza (teprotumumab) to treat thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed ...

Discover the benefits of multidisciplinary clinics for thyroid eye disease, including coordinated care, treatment options, ...

CHICAGO — Teprotumumab, a monoclonal antibody inhibitor of the IGF1 receptor, shows efficacy, including improvements in quality of life, in the treatment of moderate to severe thyroid eye disease. "In ...

Thyroid eye disease (TED) is a serious, progressive and vision-threatening autoimmune disease with a limited window of activity that can last up to three years. 3,4,5 While TED often occurs in people ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...

It can be difficult to treat a complicated autoimmune disorder such as thyroid eye disease, which is why you may need to recruit multiple doctors and experts to your healthcare team if you have the ...

This week the FDA announced the approval of the first medication to treat thyroid eye disease. The treatment reduces the characteristic bulging eyes. Following FDA approval, the treatment will soon be ...

“I’m just so tired.” “I don’t know where this extra weight came from.” “My eyes look like they’re bulging.” Is your thyroid to blame? Widespread myths about the thyroid make it challenging to know for ...